AR and metastatic prostate carcinoma: Current intensive therapies for metastatic prostate cancer include radiation, docetaxel, and novel androgen receptor signaling inhibitors, such as abiraterone, darolutamide, enzalutamide, and apalutamide, in addition to ADT [2].